ImmunityBio, Inc. (IBRX)
Summary
IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake
ImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption fuel growth, with more regulatory milestones ahead.
ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates
ImmunityBio (IBRX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.1 per share a year ago.
ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)
ImmunityBio earns a cautious buy rating as Anktiva demonstrates strong efficacy and safety in NMIBC and shows promise across broader oncology indications. IBRX's valuation now reflects significant future revenue; rapid share appreciation and anticipated dilution temper near-term upside despite robust revenue ramp and pipeline catalysts. Anktiva's combination with BCG outperforms competitors, with 84% CR in BCG-naïve NMIBC and potential label expansion pending FDA decision in early 2027.
ImmunityBio, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 325 | $2,482.94 | $2,377.37 | -$105.57 | -4.25% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 143,716 | $1.26M | $1.1M | -$160,238.76 | -12.74% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,311 | $2,595.78 | $9,963.6 | $7,367.82 | 283.84% |
| NA Nizar Araji National Bank Of Canada /FI/ | 21,618 | $165,810.06 | $165,161.52 | -$648.54 | -0.39% |
| BG Bart Gancher Intech Investment Management LLC | 78,218 | $214,912.73 | $597,585.52 | $382,672.79 | 178.06% |
ImmunityBio, Inc. (IBRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ImmunityBio, Inc. ever had a stock split?
ImmunityBio, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Richard Gerald Adcock CEO | NASDAQ (NGS) Exchange | 45256X103 CUSIP |
| US Country | 688 Employees | - Last Dividend | - Last Split | 28 Jul 2015 IPO Date |
Overview
ImmunityBio, Inc. is a clinical-stage biotechnology company that specializes in the discovery, development, and commercialization of next-generation immuno- and cellular therapies. These therapies target cancer and infectious diseases, with operations spanning the United States and Europe. The company leverages its expertise to offer cutting-edge immunotherapy and cell therapy platforms aimed at enhancing patient outcomes. Through strategic collaboration agreements and licensing arrangements with various entities, including the National Cancer Institute and Amyris, Inc., ImmunityBio is working towards advancing its promising pipeline of therapies. The company is headquartered in San Diego, California, reflecting its strong presence in one of the world’s leading biotechnology hubs.
Products and Services
- Anktiva (N-803)
- Immunotherapy and Cell Therapy Platforms
- Collaborations and Licensing Agreements
An IL-15 superagonist antibody-cytokine fusion protein, Anktiva (N-803), represents ImmunityBio’s lead biologic commercial product candidate. It is designed for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without Ta or T1 disease. This highlights ImmunityBio’s focus on addressing hard-to-treat cancers through innovative biologic treatments.
ImmunityBio’s platforms encompass a variety of immunotherapy and cell therapy solutions aimed at fighting against cancer and infectious diseases. This includes antibody cytokine fusion proteins like N-803, sophisticated vaccine delivery technologies, and natural killer cell therapies. Through these platforms, the company is able to target a broad spectrum of liquid and solid tumors, as well as other severe diseases, demonstrating its versatility and innovation in the biotechnological field.
The company’s collaborative efforts and licensing agreements with institutions such as the National Cancer Institute, LadRx Corporation, GlobeImmune, Inc., and others play a critical role in bolstering its research and development activities. These partnerships facilitate the harnessing of external expertise and technologies, thereby enriching ImmunityBio’s product pipeline and accelerating the pace of innovation in treatments for cancer and infectious diseases.
